ArticleAlimentary pharmacology & therapeutics2025
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation.
Article in Alimentary pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Safety of Biologic Therapy for Inflammatory Bowel Disease in Liver Transplant Recipients.Biomedicines · 2026Article
- Beyond the Graft: Optimizing Post-Transplant Care in Primary Sclerosing Cholangitis.Journal of clinical medicine · 2026Review
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aims'Gut-specific' biologics are associated with fewer infectious complications than 'systemic' biologics in inflammatory bowel disease (IBD) which represents an important consideration in transplant recipients. This study evaluated the safety of combining transplant immunosuppression with 'gut-specific' versus 'systemic' biologics to manage IBD following liver transplantation (LTx).
methodsA retrospective dual-centre study of IBD patients exposed to biologics following LTx between 2001 and 2023 was undertaken. Primary outcome was the incidence rate of infectious events per patient-year of biologic exposure. Infectious events were stratified by 'gut-specific' (vedolizumab) and 'systemic' (anti-TNF/ustekinumab) biologic exposure with severe events defined by hospitalisation. Secondary outcomes included the impact of non-biologic immunosuppression on the incidence of infectious and non-infectious complications.
resultsThirty-six IBD patients were exposed to 59 (median 12 [IQR 6-27] months) biologic episodes following LTx. Patients were collectively exposed to 44.5 and 44.4 patient-years of 'gut-specific' (vedolizumab = 27 [45.7%]) and 'systemic' (anti-TNF = 22 [37.2%]; ustekinumab = 10 [16.9%]) biologics, respectively. Twenty-seven (45.7%) biologic episodes were associated with 41 infectious events, a median of 8 months (IQR 4.5-13.5) following biologic initiation. Rates of infectious events were not significantly different between 'gut-specific' and 'systemic' biologic exposures (0.43 vs. 0.50 per patient-year, incidence rate ratio [IRR] 1.09 [95% CI 0.58-2.02, p = 0.79]). Corticosteroid exposure at biologic initiation was the only non-biologic immunosuppressant associated with severe infectious events (IRR 5.40 [95% CI 1.66-17.63, p < 0.01]).
conclusionIncidence of infectious events observed between IBD/LTx patients exposed to 'gut-specific' and 'systemic' biologics were similar. Biologic choice should not be influenced by concerns regarding their co-prescription with transplant immunosuppression. Corticosteroid co-therapy at biologic initiation may be associated with more severe infectious events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.